Alzheimer’s disease (AD) affects more than two million people in the United States, with prevalence estimated to increase over the next five years, imparting a substantial burden on patients,…
Acute myeloid leukemia is the most common form of acute leukemia in adults. Its incidence in the major pharmaceutical markets under study is increasing, largely as a result of the aging population…
Small cell lung cancer (SCLC) accounts for approximately 15% of all lung cancer cases and is particularly aggressive with a 5 year survival rate of just 5-10%. Historically, drug development in…
Hepatitis C virus (HCV) chronic infections are a leading cause of advanced liver disease and hepatocellular carcinoma and are a common reason for liver transplantation in Europe. The recent market…
Polycystic kidney disease (PKD) is one of the most common genetic diseases and is characterized by the development and progressive enlargement of fluid-filled cysts in the kidneys. TreatmentTrends…
European Physician and Payer Perspective on Current Mainstays and Novel Entrants in the Age of Austerity Parkinson’s disease (PD) is a debilitating chronic neurodegenerative disease affecting…
Last Updated 16 November 2015 Acute coronary syndrome (ACS)—an umbrella term that encompasses acute ST-elevation myocardial infarction (STEMI), non-ST-elevation myocardial infarction (NSTEMI),…
TreatmentTrends: Dry/Wet Age-Related Macular Degeneration 2015 (EU) is the fourth annual syndicated report that offers a snapshot of dry and wet age-related macular degeneration (AMD) market…
In recent years, biosimilars of epoetin alfa and filgrastim have been approved and launched in major markets. Uptake of these products among oncologists is increasing, driven by payers and…
Epilepsy is a debilitating neurological condition characterized by recurrent seizures that imparts a social and economic burden on patients and their caregivers. The goal of therapy is to prevent…
The malignant melanoma treatment landscape is dynamic and continues to undergo significant changes. Since 2011, three immune checkpoint inhibitors and four BRAF- or MEK-targeted agents have gained…
Last Updated 15 September 2015 Ulcerative colitis (UC) affects approximately 1.25 million people across the major markets. Aminosalicylates and corticosteroids are routinely prescribed for mild…
Ushering in a New Era of Cancer Immunotherapies in NSCLC, Malignant Melanoma, Renal Cell Carcinoma, and SCCHN The field of cancer immunotherapy has witnessed considerable advances over the past few…
Five premium-priced therapies – Xtandi (Medivation/Astellas Pharma), Provenge (Dendreon), and Xofigo (Algeta/Bayer HealthCare), Zytiga (Janssen), and Jevtana (Sanofi) – are approved in Europe…
Medical devices companies are constantly searching for growth opportunities. The largest opportunities lie within untapped emerging markets and the development of innovative technology. Analyzing…
